Preclinical insights into therapeutic targeting of KCC2 for disorders of neuronal hyperexcitability.

Duy, Phan Q; He, Miao; He, Zhigang; Kahle, Kristopher T

Duy, Phan Q; He, Miao; He, Zhigang; Kahle, Kristopher T.

Afiliação

Duy PQ; Department of Neurosurgery, Yale University School of Medicine , New Haven, CT, USA.
He M; Medical Scientist Training Program, Yale University School of Medicine , New Haven, CT, USA.
He Z; F.M. Kirby Neurobiology Center, Boston Children's Hospital, and Department of Neurology, Harvard Medical School , Boston, MA, USA.
Kahle KT; F.M. Kirby Neurobiology Center, Boston Children's Hospital, and Department of Neurology, Harvard Medical School , Boston, MA, USA.

Expert Opin Ther Targets ; 24(7): 629-637, 2020 07.

Article em En | MEDLINE | ID: mdl-32336175

Assuntos

Anticonvulsivantes/farmacologia; Epilepsia/tratamento farmacológico; Terapia de Alvo Molecular; Animais; Descoberta de Drogas; Avaliação Pré-Clínica de Medicamentos; Epilepsia/fisiopatologia; Humanos; Neurônios/metabolismo; Simportadores/metabolismo

Palavras-chave

Epilepsy; GABA; KCC2; antiepileptic drugs; chloride Homeostasis; neuronal hyperexcitability; seizure

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Epilepsia / Terapia de Alvo Molecular / Anticonvulsivantes Idioma: En Revista: Expert Opin Ther Targets Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google